Company Overview

Beyond Air, Inc. is a U.S.-based medical device and biopharmaceutical company focused on the development and commercialization of nitric oxide (NO) delivery systems for respiratory and neurological applications. The company operates primarily in the healthcare and medical technology industries, with its core business centered on generating nitric oxide from ambient air rather than relying on traditional high-pressure gas cylinders. Its flagship commercial product is the LungFit platform, which is designed to deliver precise concentrations of nitric oxide for therapeutic use in hospital settings.

The company’s principal revenue drivers include sales and deployment of the LungFit PH system, associated consumables and service arrangements, and development-stage therapeutic programs leveraging nitric oxide technology. Beyond Air primarily serves hospitals, neonatal intensive care units, and healthcare providers treating pulmonary hypertension and related respiratory conditions. The company positions itself as an innovator through its cylinder-free nitric oxide generation technology, which seeks to reduce logistical complexity, storage risks, and operating costs associated with conventional nitric oxide delivery systems. Founded in 2011 and formerly known as AIT Therapeutics, the company evolved from a development-stage medical technology business into a commercial-stage healthcare company following U.S. regulatory clearances and public market financing activities.

Business Operations

Beyond Air conducts operations through a largely integrated medical technology model that combines device engineering, clinical development, regulatory activities, and commercial distribution. Its primary operating platform is the LungFit system family, including LungFit PH, which received U.S. Food and Drug Administration approval for delivering nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. The company generates revenue through equipment placement, consumables, maintenance, and related healthcare support services tied to its nitric oxide systems.

The company’s activities span the United States and selected international markets through distribution relationships and regulatory expansion initiatives. Beyond Air also maintains development programs involving nitric oxide applications beyond pulmonary hypertension, including infectious disease and neurological research. The company has disclosed collaborations and licensing arrangements related to nitric oxide therapeutics, including interests connected to respiratory infection treatment technologies. Its operational model relies heavily on proprietary nitric oxide generation technology, intellectual property protection, regulatory approvals, and clinical validation.

Strategic Position & Investments

Beyond Air’s strategic direction centers on expanding adoption of the LungFit platform while advancing additional nitric oxide-based therapeutic applications. Growth initiatives include broadening hospital penetration in the United States, securing additional regulatory clearances internationally, and expanding indications for nitric oxide delivery systems. The company has invested substantially in clinical studies, manufacturing scale-up, and commercial infrastructure to support long-term deployment of its respiratory care technology.

The company has also pursued strategic investments and partnerships related to nitric oxide therapeutics and adjacent healthcare technologies. Beyond Air has disclosed interests in programs involving lung infections and neurological applications, reflecting a broader strategy to position nitric oxide as a versatile therapeutic modality. Its portfolio includes proprietary technology assets and patent-protected systems intended to differentiate the company from traditional nitric oxide gas suppliers. Public filings and investor materials indicate continued emphasis on product commercialization, regulatory expansion, and technology platform diversification.

Geographic Footprint

Beyond Air is headquartered in Garden City, New York, and primarily operates within the United States healthcare market. The company’s commercial focus has historically been concentrated in North America due to FDA regulatory approvals and hospital commercialization efforts. Its manufacturing, regulatory, and corporate functions are largely U.S.-based, though the company has pursued broader international opportunities through distribution and market-access initiatives.

The company has indicated strategic interest in expanding across Europe, the Middle East, and other international healthcare markets where nitric oxide therapies are utilized in critical care settings. Its global footprint remains smaller than major multinational medical device competitors, but international commercialization and regulatory expansion are part of its longer-term growth strategy. Public disclosures suggest ongoing efforts to establish broader operational and commercial influence outside the United States.

Leadership & Governance

Beyond Air’s leadership team combines experience in biotechnology, medical devices, respiratory care, and public-company management. The company’s strategic vision has focused on transforming nitric oxide delivery through scalable, cylinder-free technology intended to improve hospital efficiency and accessibility. Governance and executive oversight are directed by a board and management team with backgrounds in healthcare commercialization, regulatory affairs, and medical innovation.

Key executives include:

• Steve Lisi – Chairman and Chief Executive Officer
• Douglas Rahn – Chief Financial Officer
• Amir Avniel – Chief Operating Officer
• Johnnie Copeland – Chief Commercial Officer
• Robert Carey – Chief Business Officer

The leadership team has emphasized regulatory execution, commercialization of the LungFit platform, and expansion of nitric oxide applications into additional therapeutic areas. Corporate governance and operational disclosures are primarily detailed through SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and investor presentations.